Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Treatment of patients with chronic pruritus of unknown origin with dupilumab
By
- AMS
posted
Feb 09, 2021 08:03 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data
- AMS
Added Oct 29, 2020
Blog Entry
Safety of dupilumab in atopic patients during COVID-19 outbreak
- AMS
Added Jun 19, 2020
Blog Entry
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry
- AMS
Added Jun 21, 2021
Blog Entry
Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020)
- AMS
Added Jul 21, 2021
Blog Entry
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis
- AMS
Added Jul 03, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic